Bausch & Lomb Incorporated v. ZeaVision LLC

CourtDistrict Court, E.D. Missouri
DecidedAugust 31, 2022
Docket4:22-cv-00914
StatusUnknown

This text of Bausch & Lomb Incorporated v. ZeaVision LLC (Bausch & Lomb Incorporated v. ZeaVision LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bausch & Lomb Incorporated v. ZeaVision LLC, (E.D. Mo. 2022).

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK

BAUSCH & LOMB INCORPORATED, et al,

Plaintiffs, Case # 20-CV-06452-FPG v. DECISION AND ORDER

ZEAVISION LLC,

Defendant.

INTRODUCTION Plaintiffs Bausch & Lomb Incorporated (“Bausch & Lomb”) and PF Consumer Healthcare 1 LLC (“PF Consumer Healthcare 1”) (collectively, “Plaintiffs”) bring this 35 U.S.C. § 271 action against Defendant ZeaVision LLC (“ZeaVision” or “Defendant”) for alleged infringement of U.S. Patent Nos. 6,660,297 and 8,603,522 (collectively, the “Patents-in-Suit”). ECF Nos. 1, 21. In response, Defendant filed a Motion to Dismiss or Transfer Venue. ECF No. 21. Plaintiffs responded in opposition, ECF No. 24, and Defendants replied, ECF No. 26. For the reasons set forth below, Defendant’s Motion is GRANTED. BACKGROUND Bausch & Lomb is a (i) New York corporation with a principal place of business in Rochester, New York, and a (ii) wholly owned subsidiary of Bausch Health Americas, Inc., a Delaware corporation. ECF No. 1. PF Consumer Healthcare 1 is a Delaware limited liability company with a principal place of business in Delaware. Id. ZeaVision is also a Delaware limited liability company, with a principal place of business in Chesterfield, Missouri, located in the Eastern District of Missouri. Id. Plaintiffs and Defendant produce similar eye vitamin products that treat macular degeneration. Id. The patents-in-suit cover Plaintiffs’ products. Id. Bausch & Lomb and PF Consumer Healthcare 1, as joint owners of the patents-in-suit, allege inter alia that ZeaVision is infringing, inducing infringement of, and/or contributing to the infringement of the patents-in-suit in the United States by making, using, offering to sell, selling, or importing compositions, methods,

components, or materials covered by the patents-in-suit. Id. ZeaVision moves for dismissal of the action for improper venue or, in the alternative, transfer to the Eastern District of Missouri. ECF No. 21. Plaintiffs do not dispute venue is presently improper in the Western District of New York, but maintain the District of Delaware is a more appropriate venue. ECF No. 24. Several pending or dismissed lawsuits among the parties affect the Court’s treatment of Defendant’s present Motion. For the purposes of this Decision and Order, the Court lists them by

venue and in chronological order. A. Western District of New York

On June 30, 2020, Plaintiffs filed its present Complaint against Defendant, as well as ten other similar complaints against different defendants, in which Plaintiffs allege infringement of the patents-in-suit. ECF No. 1. On January 19, 2021, ZeaVision moved to dismiss or transfer the complaint, ECF No. 16. On February 8, 2021, Plaintiff filed an Amended Complaint, in which it included false advertising and unfair competition claims. ECF No. 20. On February 22, 2021, ZeaVision again moved to dismiss or transfer the Amended Complaint for improper venue. ECF No. 21. The parties do not dispute venue is improper with respect to ZeaVision in the District. See ECF 21, 24, 26. Plaintiffs allege they expected Defendant to waive its improper venue defense as a result of discussions that occurred between the parties. ECF No. 24, 28. Defendant disputes this. ECF No. 21. B. Eastern District of Missouri

On January 19, 2021, ZeaVision filed a Declaratory Judgment Complaint against Plaintiffs in the Eastern District of Missouri that involves the patents-in-suit in the present action. See ZeaVision LLC v. Bausch & Lomb Inc., No. 4:21-CV-00072 JAR, 2021 WL 5905986, at *1 (E.D. Mo. Dec. 14, 2021). ZeaVision’s Complaint requested orders declaring that ZeaVision’s products do not infringe any the patents-in-suit, as well as an order declaring that the labeling and marketing claims of ZeaVision’s products do not violate false advertising or state unfair competition laws. Id. On December 14, 2021, the U.S. District Court for the Eastern District of Missouri dismissed the action for (i) lack of personal jurisdiction over Bausch & Lomb and (ii) because the present action and Motion, ECF No. 21, is pending here in the Western District of New York and the Court

believed it “prudent” to allow this Court to determine the venue question first. Id at *6. On December 20, 2021, ZeaVision filed another Complaint against Bausch & Lomb in the Eastern District of Missouri alleging violations of the Clayton and Sherman Antitrust Acts and the Lanham Act. See Complaint at 1, ZeaVision LLC v. Bausch & Lomb Inc., No. 4:21-CV-01487 (E. D. Mo. filed Dec. 20, 2021). In the Complaint, ZeaVision alleged that the present Bausch & Lomb patent infringement action brought in the Western District of New York is “sham litigation” and

part of a broader business strategy executed in violation of federal antitrust laws. Id; see also ECF No. 29. The action remains pending in the Eastern District of Missouri. ECF No. 29. C. District of Delaware

On June 30, 2020, Plaintiffs filed a Complaint against SBH Holdings LLC (“SBH”), a Delaware limited liability company and non-party to the present action or any of the above actions, in the Western District of New York, alleging infringement of the patents-in-suit. See Bausch & Lomb Inc. v. SBH Holdings LLC, No. 20-cv-06451 (June 2020, W.D.N.Y.). On October 1, 2020, SBH moved to dismiss the action for improper venue under Rule 12(b)(3). Id. On November 2, 2020, Plaintiffs voluntarily dismissed the Complaint under Rule 41(a)(1)(A)(i). Id. On October 28, 2020, Plaintiffs brought the same action for patent infringement against

SBH, but in the District of Delaware. See Bausch & Lomb Inc. v. SBH Holdings LLC, No. CV 20- 1463-LPS, 2022 WL 856750, at *1 (D. Del. Mar. 23, 2022). The action remains pending. Id. DISCUSSION “Venue provisions are designed […] to allocate suits to the most appropriate or convenient forum.” Brunette Mach. Works, Ltd. v. Kockum Indus., Inc., 406 U.S. 706, 710 (1972). The patent venue statute, 28 U.S.C. § 1400(b), provides that “[a]ny civil action for patent infringement may be brought in the judicial district where the defendant resides, or where the defendant has committed acts of infringement and has a regular and established place of business. “As applied to domestic corporations, ‘reside[nce]’ in § 1400(b) refers only to the State of incorporation.” TC Heartland LLC v. Kraft Foods Group Brands LLC, 137 S. Ct. 1514, 1521 (2017).

A party may move to dismiss an action for improper venue pursuant to Federal Rule of Civil Procedure 12(b)(3). A “plaintiff bears the burden of establishing that venue is proper once venue is challenged.” Tour Tech. Software, Inc. v. RTV, Inc., 377 F. Supp. 3d 195, 200 (E.D.N.Y. 2019). In deciding a motion to dismiss for improper venue, a court “may consider facts outside the pleadings . . . [including] declarations and exhibits attached to [Plaintiffs’] Complaint and in support of the parties’ memoranda.” Id. When venue is improper, a court “shall dismiss, or if it be in the interest of justice, transfer such case to any district or division in which it could have been brought.” 28 U.S.C. § 1406(a). “Courts enjoy considerable discretion in deciding whether to transfer a case in the interest of justice.” Daniel v. Am. Bd.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

FPC CORP. v. Uniplast, Inc.
994 F. Supp. 945 (N.D. Illinois, 1998)
Herbert Ltd. Partnership v. Electronic Arts Inc.
325 F. Supp. 2d 282 (S.D. New York, 2004)
O'Brien & Gere, Inc. of North Am. v. Barton Rands
497 F. Supp. 2d 507 (W.D. New York, 2007)
TC Heartland LLC v. Kraft Foods Group Brands LLC
581 U.S. 258 (Supreme Court, 2017)
Tour Tech. Software, Inc. v. RTV, Inc.
377 F. Supp. 3d 195 (E.D. New York, 2019)
Daniel v. American Board of Emergency Medicine
428 F.3d 408 (Second Circuit, 2005)
D.H. Blair & Co. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
Sepanski v. Janiking, Inc.
822 F. Supp. 2d 309 (W.D. New York, 2011)
EasyWeb Innovations, LLC v. Facebook, Inc.
888 F. Supp. 2d 342 (E.D. New York, 2012)
Everlast World's Boxing Headquarters Corp. v. Ringside, Inc.
928 F. Supp. 2d 735 (S.D. New York, 2013)
Dickerson v. Novartis Corp.
315 F.R.D. 18 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Bausch & Lomb Incorporated v. ZeaVision LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bausch-lomb-incorporated-v-zeavision-llc-moed-2022.